Real‐world outcomes of 18,186 metastatic solid tumor outpatients: Baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapy
Cancer Medicine · 2023
DOI: 10.1002/cam4.6645 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer Medicine, 2023. Verfasst von Jerome H Goldschmidt und 9 weiteren Autor:innen. Beteiligte Einrichtung: US Oncology, Inc, The Woodlands, Texas, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Carcinoma, Renal Cell. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Partner Therapeutics, Inc..
Abstract (Originalsprache)
Background
Patient survival in advanced/metastatic melanoma, non‐small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) has improved with immune checkpoint inhibitors (ICI). Biomarkers' role in prognosis and treatment has been limited by conflicting trial results.
Methods
This retrospective, observational study analyzed baseline demographic, clinical, laboratory, and treatment data versus outcomes of The US Oncology Network adult outpatients. Patients with advanced/metastatic melanoma, NSCLC, or RCC treated between January 1, 2015 and November 30, 2020 were given ICI monotherapy or combination therapy with ipilimumab, pembrolizumab, nivolumab, or atezolizumab. Treatment outcomes (overall survival [OS], time to treatment discontinuation, time to next treatment) were followed longitudinally until May 31, 2021, last patient record, or date of death. Baseline blood cell counts, including absolute monocyte count (AMC), absolute lymphocyte count (ALC), monocyte‐to‐lymphocyte ratio (MLR), absolute neutrophil count (ANC), and eosinophil count, were subdivided into quintiles for univariate and multivariable Cox regression analyses.
Results
Data from 18,186 patients with advanced/metastatic melanoma ( n = 3314), NSCLC ( n = 12,416), and RCC ( n = 2456) were analyzed. Better OS correlated with increased baseline serum albumin concentration, increased eosinophil and lymphocyte counts, and Western United States physician practice location. Decreased OS correlated with increased AMC, MLR, ANC, age, and worse Eastern Cooperative Oncology Group performance status.
Conclusions
To our knowledge, this study is the largest to date to associate baseline survival indicators and outcomes in outpatients with advanced/metastatic melanoma, NSCLC, or RCC and receiving ICIs. Results may inform disease‐specific prognostic models and help providers identify patients most likely to benefit from ICI therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- US Oncology, Inc, The Woodlands, Texas, USA.
- Ontada, Irving, Texas, USA.
- Partner Therapeutics, Inc, Lexington, Massachusetts, USA.
- Department of Medicine, Division of Hematology and Oncology, Case Western Reserve University, Cleveland, Ohio, USA.
ORCID-Profile: Lin-Na Chou, Philip K Chan, Joyce Kinsey, Katherine Pitts, Matt Nestor, Edwin P Rock, Hillard M Lazarus
Förderung
- Partner Therapeutics, Inc.
Zitieren
APA
Goldschmidt, J. H., Chou, L. N., Chan, P. K., Chen, L., Robert, N., Kinsey, J., Pitts, K., Nestor, M., Rock, E. P., & Lazarus, H. M. (2023). Real‐world outcomes of 18,186 metastatic solid tumor outpatients: Baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapy. Cancer Medicine. https://doi.org/10.1002/cam4.6645
Vancouver
Goldschmidt JH, Chou LN, Chan PK, Chen L, Robert N, Kinsey J, et al. Real‐world outcomes of 18,186 metastatic solid tumor outpatients: Baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapy. Cancer Medicine. 2023. doi:10.1002/cam4.6645
BibTeX
@article{Goldschmidt2023,
author = {Goldschmidt, Jerome H and Chou, Lin-Na and Chan, Philip K and Chen, Liwei and Robert, Nicholas and Kinsey, Joyce and Pitts, Katherine and Nestor, Matt and Rock, Edwin P and Lazarus, Hillard M},
title = {Real‐world outcomes of 18,186 metastatic solid tumor outpatients: Baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapy},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6645}
}
EUVIMED